Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
about
Opioid-induced constipation: advances and clinical guidanceFitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can FlyChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.Medicinal chemical properties of successful central nervous system drugsInteraction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.Relationship between P-glycoprotein and second-generation antipsychotics.Itraconazole and domperidone: a placebo-controlled drug interaction study.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesImprovement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancerCell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Enhanced intestinal absorption of daidzein by borneol/menthol eutectic mixture and microemulsionDevelopment of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyAbsorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjectsWhich in vitro screens guide the prediction of oral absorption and volume of distribution?Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.Mitigating permeability-mediated risks in drug discovery.Fexofenadine hydrochloride in the treatment of allergic disease: a reviewOpioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.Renal Drug Transporters and Drug Interactions.Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples.Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein.Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination.Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies.Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein.Three- and four-class classification models for P-glycoprotein inhibitors using counter-propagation neural networks.Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography.Recovery of an antidepressant from pharmaceutical wastes using ionic liquid-based aqueous biphasic systems
P2860
Q26765571-60D93FF1-2A56-4359-95F1-18B0AE411C71Q26780025-33ABFDDA-2ABA-44B5-81C5-89AEA093380DQ28083547-75D8E78F-18F3-43AD-9E4C-7389E6A547B5Q30234940-7DD9460B-A7EA-4412-B5DD-293D6743FF70Q33588365-2A9C3876-8CE1-4221-8B00-B218B9D2404EQ33946968-C8C0D47E-99B5-4914-9482-538D618B655FQ34116212-FD0307F8-AC42-4A5E-A6CA-2868AD687583Q34208133-6FD074F5-E86D-4618-AD26-E44B557AEA16Q34261356-4B0F3472-E9B3-4EAF-A8F2-DE0E26A1554DQ34657381-D0B2A934-935B-4A72-8687-851FF8FD0868Q35090489-7924549F-1AE4-44AB-9405-FB95FBA2E883Q35194750-434C8955-61BF-4D27-AC43-B42884D41859Q35577248-3F87EDE4-F70E-4940-BA72-3F58A85A0A20Q35797203-D663B1E8-B2C9-491E-9876-780AC9764BD5Q36044477-415D2859-0F76-45A1-BF02-99DCC6C11DBEQ36055558-EC2F73A5-5BC7-4589-8266-A71BF49C423DQ36159042-BB4668F7-7430-480A-ADE2-586B6214305CQ36691249-F4535372-176B-4EFC-90DE-A51427E8C730Q37671826-52B2CDE3-5DA2-4765-B1D7-A0A151AC16BCQ37857671-5F576B9B-390A-41D8-9D5E-BB5FCBB1D34FQ38772298-039848C9-90A5-47B3-922A-6D0647C1090EQ39062861-D883094F-5489-4319-8452-3ABACB3757ADQ39113007-AB80BD51-61BA-4ABD-ADFA-867760FAF3D8Q39140289-289CF603-AFF6-405E-BAAE-3F7B521AAEA6Q39539298-B46C9B76-F122-486A-998F-59BDDD438AD7Q42284764-06E81B57-1A2D-4521-BEE7-74715CF2436CQ42383217-A51F7803-4DBA-4786-B1BF-1F7E2DC4A244Q43156419-6E76EDD9-43D8-4177-B82F-D27C6B75C2FDQ46253927-D461453E-3503-49DE-BF64-7C4A96899EF6Q46543591-1B15E517-C381-457E-8650-1DD485F83461Q50976814-81D43D85-53C0-4D08-898F-B32C6F49C5CAQ54396045-6FD3A5F2-BCDC-4F7D-87DF-80CB22DAE213Q57663214-9FCEF574-2CD6-400C-A9FD-1E4916C1BD77
P2860
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@en
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@nl
type
label
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@en
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@nl
prefLabel
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@en
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@nl
P2093
P1476
Caco-2 permeability, P-glycopr ...... tration of heterocyclic drugs.
@en
P2093
Fried Faassen
Gerard Vogel
Henry Spanings
Herman Vromans
P304
P356
10.1016/S0378-5173(03)00372-7
P407
P577
2003-09-01T00:00:00Z